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Abstract  
In our previous study,  we isolated from chloroform extract of the bulbs of orchid P. michuacana, three antioxidant compounds: two stilbene α-α´-dihydro, 
3´,5´,2-trimethoxy-3-hydroxy-4-acetyl-4´-isopentenyl stilbene, 5-[2-(3-hydroxy-5-methoxyphenyl)ethyl]-2-methoxyphenol (gigantol) and one phenanthrene 
4,6,7-trihydroxy-2-methoxy-8-(methylbut-2-enylphenanthren-1-1´-4´,6´,7´-trihydroxy-2´-methoxy-8´-(methylbut-2´-enyl)-phenanthrene. Following the study, 
we investigated the ability of isolated compounds to inhibit advanced glycation in vitro. Bovine serum albumin was glycated in the presence of glucose or 
methylglyoxal. Amadori-rich protein was prepared by dialyzing lysozyme that had been glycated by ribose. We also evaluated renal function by checking 
formation of advanced glycation and tail tendon collagen quality in streptozotocin-induced diabetic mice. Also determined the effect on LDL and 
hemoglobin. Compounds can efficiently inhibit the formation of AGEs by trapping reactive methylglyoxal and showed potent anti-Amadorin activity. Also 
exhibited a significant inhibitory activity on the glycated  hemoglobin (GHb and HbA1c). Compounds showed a protective renal effect and reduction in mice 
tail tendon collagen. Also the tested compounds are potent agents for protecting LDL against oxidation and glycation. We concluded that compounds from P. 
michuacana are potent antiglycation agents, which can be of great value in the prevention of diabetic glycation-associated-pathogenesis. 
 
Keywords: Prosthechea michuacana; antiglycation; stilbenoids; phenanthrene; streptozotocin-induced diabetic mice  
 
Resumen 
En un estudio anterior, aislamos del extracto clorofórmico de los bulbos de la orquídea Prosthechea michuacana, tres compuestos antioxidantes: los 
estilbenos α-α´-dihidro, 3´,5´,2-trimethoxi-3-hidroxi-4-acetil-4´-isopentenil-stilbeno, 5-[2-(3-hydroxy-5-methoxyphenyl)ethyl]-2-methoxyphenol (gigantol) y   
el fenantreno 4,6,7-trihidroxi -2-methoxi-8-(metilbut-2-enilfenantren-1-1´-4´,6´,7´-trihidroxi-2´-metoxi-8´-(metilbut-2´-enil)-fenantreno. Continuando con el 
estudio, investigamos la capacidad de estos compuestos para inhibir la glicación avanzada in vitro. La seroalbúmina bovina se glicosiló en presencia de 
glucosa o metilglioxal. La reacción de Amadori se determinó con lisozima glicosilada previamente tratada con ribosa. También se evaluó la función renal 
mediante la formación de la glicación avanzada y la inhibición de AGEs en el ensayo sobre el colágeno del tendón de la cola en ratones con diabetes inducida 
con estreptozotocina. También determinamos el efecto de los compuestos aislados sobre LDL y hemoglobin. Los compuestos pueden inhibir eficazmente la 
formación de AGE atrapando el metilglioxal reactivo y muestran potente actividad anti Amadorin. También mostraron una actividad inhibitoria significativa 
en la formación de la hemoglobina glucosilada, GHB y HbA1c. Mostraron un efecto protector renal y una reducción en el colágeno glicosiladó del tendón de 
la cola. También estos compuestos son potentes agentes para la protección de LDL frente la oxidación y la glicación. En base a los resultados obtenidos se 
concluye que los compuestos aislados son potentes agentes antiglicación, que pueden ser de gran valor en la prevención de la patogénesis de la diabetes 
asociada a la glicación. 
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Lista de abreviaciones: AGEs: productos finales de la 
glicación avanzada; BSA: albumina de sérica bovina   
 
INTRODUCTION  
Advanced glycation end-products (AGEs) are the final 
products of the nonenzymatic reaction between 
reducing sugars and amino groups in proteins, 
lipoproteins and nucleic acids. They are a group of 
complex and heterogeneous compounds that are 
known as brown and fluorescent cross-linking 
substances such as pentoside, nonfluorescent cross-
linking products like methylglyoxal-lysine dimers, or 
nonfluorescent, non-cross-linking adducts such as 
carboxymethyllysine and pyrraline, a pyrrole aldehyde 
(Rahbar and  Figarola, 2002). AGEs accumulation in 
vivo has been considered to play a major role in the 
pathogenic process of diabetes and its complications, 
including neuropathy, nephropathy, retinopathy, and 
cataract (Ahmed, 2005) and in other health disorder 
such as atherosclerosis (Kune et al., 1978), 
Alzheimer´s disease (Vitek et al., 1994), and aging 
(Brownlee, 1995). Thus, the discovery and 
investigation of compounds with an AGEs inhibitor 
activity, would certainly offer a potential therapeutic 
approach for the prevention of diabetes or other 
pathogenic complications. 
Prosthechea michuacana (Lex.) W. E Higgins 
(PM) belong to the family Orchidaceae. Mixteco and  
Zapoteco natives of Oaxaca Mexico, give to this plant 
several uses: As food they collect the bulbs and eat 
them raw to eliminate thirst or liquefy them with water 
to prepare a drink, that is also used as anti-
inflammatory, to depurate the circulatory system, treat 
renal disease, and diabetes (Perez, 2010). During 
November and December, this beautiful orchid is used 
for religious purposes as a decorative element in the 
traditional "Birth" (Flores and Manzanero, 1988). We 
have previously reported the relaxant and 
antispasmodic effect of this plant on isolated guinea 
pig ileum (Vargas and Perez, 2009a), hepatoprotective  
activity, ability to inhibit oxidative stress in liver 
(Perez and Vargas, 2009b; Perez and Hoyos, 2011), 
anti-inflammatory and wound healing properties 
(Perez and Vargas, 2009a), nephroprotective (Perez et 
al., 2010a) antioxidant activities (Perez et al., 2010b) 
and anti-diabetic activity (Perez and Vadillo, 2011). 
The aim of this study, is to investigate the AGEs 
inhibition capacity of two stilbenoid and one 
phenanthrenes previously isolated from the bulbs of 
Prosthechea michuacana. 
MATERIALS AND METHODS 
Reagents 
All chemicals and reagents used in this study were 
purchased from Sigma chemical Co (St. Louis, MO, 
USA). All reagents used were of analytical grade. 
GlycoGel II column (Pierce, Rockford, IL), 
 
General Experimental Procedures 
The fluorescence was measured using Aminco 
Bowman Luminescence spectrometer (USA). The 
amount of glycated hemoglobin (% GHb) was 
determined using an ion capture component set (IMx 
system, Abbott laboratories, USA). Absorbance was 
recorded by a Hitachi U-2001 spectrometer. 
 
In vitro glycation of proteins 
The methodology was based on that of Brownlee et al. 
(1986). Bovine serum albumin (BSA) (l0 mg/ml) was 
incubated with glucose (500 mM) in phosphate 
buffered-saline (PBS) (5 ml total volume, pH 7.4) or 
0.1 M methylglyoxal, containing 0.02% sodium azide 
at 37 °C. All of the reagent and samples were 
sterilized by filtration through 0.2 µm membrane 
filters. The protein, the sugar and the prospective 
inhibitor were included in the mixture simultaneously. 
Aminoguanidine was used as an inhibitor positive 
control. Reactions without any inhibitor were also set 
up. Each solution was kept in the dark in a capped 
tube, incubation time was 15 days, and carried out by 
triplicate. The formation of AGEs was firstly assessed 
by the characteristic fluorescence (excitation 
wavelength of 370 nm and emission wave-length of 
440 nm). 
Percent inhibition was calculated as follows: 
 
Inhibition% = [1-(As-Ab)/(Ac-Ab)] x 100 
 
Where: 
As = fluorescence of the incubated mixture with 
sample 
Ac, Ab = are the fluorescence of the incubated mixture 
without sample as a positive control and the 
fluorescence of incubated mixture without sample as a 
blank control. 
 
BSA-Methylglyoxal Assay 
This assay was modified from on a published method 
(Peng et al., 2008). The assay evaluates the middle 
stage of protein glycation. BSA and methylglyoxal 
were dissolved in phosphate buffer (100 mM, pH 7.4) 
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to a concentration of 20 mg/ml and 60 mM, 
respectively. Compounds at concentration of 500 to 
2000 µM were dissolved in the same phosphate buffer. 
1 ml of the BSA solution was mixed with 1 ml of 
methylglyoxal solution and 1 ml of tested compounds. 
The mixture was incubated at 37 °C. Sodium azide 
(0.2 g/l) was used as an aseptic agent. Phosphate 
buffer was used as a blank. Aminoguanidine and 
phloroglucinol were used as positive controls. After 
seven days of incubation, fluorescence of the samples 
was measured using an excitation of 340 nm and an 
emission of 420 nm, respectively. 
The % inhibition of AGE formation = [1 –  
(fluorescence of the test group/ 
fluorescence of the control group)] x 100% 
 
Amadorin activity  
Amadorin activity was determined using a post-
Amadori screening assay (Khalifah et al., 1999). 
Lysozyme (10 mg/ml) was incubated with 0.5 M 
ribose in 0.1 M sodium phosphate buffer containing 3 
mM sodium azide, pH 7.4 at 37 °C for 24 h. Unbound  
ribose  was removed by dialysis against 4 1 of 0.1 M  
sodium  phosphate  buffer,  Ph  7.4  at  4 °C for  48 h  
with 5-6 changes. Following dialysis, the protein 
concentration was determined using the Bio-Rad   
standard protein assay kit based on the Bradford dye-
binding procedure (Bradford, 1976). Dialysed ribated 
lysozyme (10 mg/ml) was reincubated with 5-50 mM 
of compounds isolated and aminoguanidine in 0.1 M 
sodium phosphate buffer containing 3 mM sodium 
azide, pH 7.4 at 37 °C for 15 days.  
 
Glycation of hemoglobin 
Glassware was previously sterilized. The experiment 
was performed on a specially treated bench to avoid 
any possible contamination. Glucose (0.278 mg/dl), 
hemoglobin (30 mg/dl), isolated compound (5 mg/dl), 
and glutathione (0.5 mM) were dissolved in distilled-
sterilized water. This hemoglobin solution was diluted 
with three times of water to prepare the negative 
control. Hemoglobin, glucose, and water were mixed 
at a ratio of 1:1:2 (v/v/v). Isolated compounds or 
glutathione was added instead of water to the positive 
control group. These mixtures were incubated for 5 
days at 37 °C with continuous stirring (70 rpm). The 
amount of glycated hemoglobin (% GHb) was 
determined using an ion capture component set (IMx 
system, Abbott laboratories, USA). The amount of 
hemoglobin Alc (% HbAlc) was calculated by defining 
the equation used to convert IMx glycated hemoglobin 
(% GHb) to standardized percent of hemoglobin Alc 
(% HbAlc).  
 
LDL oxidation measurement 
Amphotericin B was dissolved in methanol first and 
then added to an LDL solution, with or without 
compound treatment, for final concentration of 5 and 
10 µM of Amphotericin B. 1 ml of CuS04 (10 µM)  
was used to initiate LDL oxidation in 10 ml of an 
LDL solution sample. After incubating the LDL 
solution at 37 °C for 72 h, the method of Jain and 
Palmer (1997)  was used to measure malondialdehyde 
(MDA) formation (nmol/mg LDL protein). Briefly, 
0.2 ml LDL solution was suspended in 0.8 ml PBS.  
Then 0.5 ml trichloroacetic acid (TCA; 30%) was 
added. After vortexing and standing in ice for 2 h, 
samples were centrifuged at 1500 x g for 15 min. 
Supernatant (1 ml.) was mixed with 0.25 ml, 
thiobarbituric  acid (TBA) (1%), and the mixture was 
heated in a boiling water bath for 15 min. The 
concentration of MDA-TBA complex was assayed at 
532 nm.  
The formation of conjugated diene (CD), a 
lipid oxidation product, in LDL also was determined 
according to the method described by Esterbauer et al. 
(1989). The lipid oxidation of an LDL solution 
containing 5 or 10 µM of each compound was 
initiated at 37 °C by 0.1 mM CuCl2. Absorbance at 
234 nm was continuously recorded for 60 min at 37 
°C by a Hitachi U-2001spectrometer with a constant 
temperature recirculator. The lag phase, expressed in 
minutes, was defined as the period where no oxidation 
occurred. A longer lag phase indicated less CD 
formation.  
 
In vitro glycation of LDL 
LDL glycation was performed according to the 
method described in Li et al. (1996).  Briefly, 50 mM 
glucose in PBS (pH 7.4) was added to an LDL 
solution with and without compound treatment. 
Sodium azide at 0.02% was used as antibiotic to 
prevent bacterial growth. This solution was sterile 
filtered, covered with N2, and stored for 6 d at 37 ºC 
in the dark. After glycation, the solutions were 
dialyzed against PBS (20 ml, against 4 l) at 4 °C for 
40 h. Then glycated LDL was separated from 
nonglycated LDL by applying a GlycoGel II column 
(Pierce, Rockford, IL), in which 500 µl LDL solution 
was loaded on the column, and glycated LDL was 
eluted with 2 ml, sorbitol buffer, pH 10.25. Neither 
copper nor any other oxidant was used for the 
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experiments on LDL glycation. The method of Duell 
et al. (1990) was used to measure LDL glycation 
level. LDL solution (200 µl) was mixed with 200 µl 
4% NaHC03 and 200 µl 0.1% trinitrobenzoic acid. 
This mixture was flushed with N2, sealed, and 
incubated at 37 °C in the dark. After 2 h, the 
absorbance at 340 nm was measured 
spectrophotometrically. The blank was a mixture of 
LDL and NaHCO3 in PBS. LDL glycation is reported 
as relative reduction in the level of free ε-amino 
groups of L-lysine when compared with LDL solution 
in the absence of glucose. During LDL glycation, 
samples were treated with or without EDTA (0.5 
mM), and LDL oxidation level was also determined.  
 
Experimental animals 
Study was conducted in CD1 mice weighting about 
20-30 g. They were procured by the bioterium of the 
National School of Biological Sciences IPN and were 
housed in microlon boxes in a controlled environment 
(temperature 25 ± 2 ºC) with standard laboratory diet 
and ad libitum water. Animals were acclimatized for a 
period of three days in their new environment before 
initiating the experiment. Litter was renewed three 
times a week to ensure hygiene and maximum comfort 
of the animals.  Ethical clearance for handling animals 
(NIH publication Nº 85-23 revised 1985) was 
observed.  
 
In vivo glycation of proteins 
Experimental design 
We used male mice (4-5 weeks  age, 20-30 g) kept in 
wire-bottomed cages, and exposed to a 12-h light/dark 
cycle. The room temperature and humidity were 
maintained automatically at about 25 °C and 60%, 
respectively. These animals had ad libitum access to 
commercial food (Purina) and water. After several 
days of adaptation, the mice were randomly separated 
into normal control (n = 5) and diabetic groups. The 
diabetic groups were given an intraperitoneal (i.p.) 
injection of streptozotocin (45 mg/kg body weight in 
10 mM citrate buffer (pH 4.5). Animals receiving an 
injection of citrate buffer were used as a normal 
control. After 10 days of the streptozotocin or vehicle 
injection, the blood samples were obtained from the 
tail vein between 10:00 and 11:00 am, avoiding the 
influence of food consumption and where used to 
determine glucose levels. Mice with a blood glucose 
level higher than 300 mg/dl were used as diabetic 
mice: and randomly divided into five experimental 
groups. Diabetic animals were treated orally with the 
tree compounds dissolved in water at doses of 15 
mg/kg/day by oral gavage while their control group 
was only given water. Fourteen days later, after renal 
perfusion through the renal artery with ice-cold 
physiological saline, the kidneys were removed from 
each mouse. 
 
Serum parameters  
Serum glycosylated protein was measured by the 
thiobarbituric acid assay of McFarland et al. (1979) in 
which non-enzymatically bound glucose is released as 
5-hydroxymethylfurfural and quantitated 
colorimetrically.  
   
AGE Level in kidney 
The renal AGEs level was determined by the method 
of Nakagawa (1993). In brief, minced kidney tissue 
was dilapidated with chloroform and methanol (2: 1, 
v/v) overnight.  After  washing,  the  tissue was 
homogenized  in  0.1  N NaOH,  followed   by 
centrifugation  at  8000 x g  for 15 min at 4 °C.  The 
amounts of AGEs  in  these  alkali-soluble samples 
were determined  by  measuring  the  fluorescence  at 
an   emission   wavelength   of   440   nm   and   an   
excitation  wave length  of  370 nm. A native BSA 
preparation (l mg/ml of 0.1 N NaOH) was used as a 
standard, and its fluorescence intensity was defined     
as one unit of fluorescence. The fluorescence values of 
samples were measured at a protein concentration of 
1mg/ml and expressed in arbitrary units (AU).  
 
Glycation of tail tendon collagen 
Tendons separated from tails of experimental mice 
were washed thoroughly in saline solution at 4 ºC. 
Acid hydrolysis of the tendons was carried out at 121 
ºC for 4 h. Hydroxyproline was estimated in 
hydrolysed tendon collagen samples according to the 
method of Woessner (1961). Collagen content in the 
mouse tail tendon was expressed in mg collagen/100 
mg tissue assuming that collagen weights 7.46 times 
hydroxyproline. Extent of collagen glycation in tail 
tendon was assessed by phenol-sulfuric acid method 
(Rao and Pattabiraman, 1989) and expressed as, µg of 
glucose/mg collagen. Clean tendons (50 mg, wet 
weight) were digested in freshly prepared pepsin 
solution (1 mg/ml in 0.5 M acetic acid, 5 ml) for 24 h 
at 37 ºC to determine the amount of pepsin soluble 
collagen (Golub et al., 1978). Samples of pepsin-
digested collagen (0.25 ml) were mixed with 2.75 ml 
of 200 mM phosphate buffer (pH 7.5). Collagen linked 
fluorescence was quantified at 365 nm excitation and 
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416 nm emission, relative to the standard quinine 
sulfate solution (1 µg/ml) and expressed as AU/mg 
collagen (Stefek et al.,  2000).  
 
Statistical Analysis 
Data are presented as means ± S.E.M. The effect of 
isolated compounds 1 to 3 on each parameter was 
examined using the one way Analysis of Variance. 
Individual differences among groups were analyzed by 
Dunnett's test and significance was accepted at p < 
0.05. 
 
RESULTS AND DISCUSION 
Repeated chromatography of the chloroform residue 
from bulbs of P. michuacana led to the isolation and 
characterization of α-α´-dihydro, 3´,5´,2-trimethoxy-3-
hydroxy-4-acetyl-4´-isopentenylstilbene (1) 4,6,7-
trihydroxy-2-methoxy-8-(methylbut-2-enyl 
phenanthren)-1-1´-4´,6´,7´-trihydroxy-2´-methoxy-8´-
(methylbut-2´-enyl)  phenanthrene (2)  and gigantol 
(3) (Figure 1). The structures were elucidated based on 
1-dimensional (
1
H- and 
13
C-NMR) and 2-dimensional 
NMR heteronuclear multiple bonding connectivity 
(HMBC) spectral data analysis and by comparison 
with published spectral data. We have previously 
reported the elucidation of the structure and their 
antioxidant effect on DPPH and ABTS radical 
scavenging and anti-lipid peroxidation activities 
(Perez et al., 2010b). 
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Figure 1 
Chemical structures of compounds 1-3 isolated from Prosthechea michuacana 
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Table 1 
The inhibitory effects of chloroform extract from P. michuacana (PM), compounds 1, 2, 3 and 
aminoguanidine on the formation of advanced glycation end products (AGEs), in vitro induced by glucose 
and methylglyoxal 
                   Inducer                            Treatment                                                    AGEs 
                                                                                                                                           IC50 
 Chloroform extract (PM) 74.6 µg/ml 
 1 24.5 µM 
Glucose 2 71.6 µM 
 3 28.7 µM 
 Aminoguanidine 57.3 µM 
   
 1 1013.7 µM 
Methylglyoxal 2 1578.9 µM 
 3 1018.4 µM 
 Aminoguanidine 910.9 µM 
 
In order to determine the inhibitory effect of 
the three isolated compounds on AGEs formation, 
several assay methods have been proposed including 
assays based on inhibition of specific fluorescence 
generated during  the course of glycation and AGEs 
formation, and assays based on the inhibition of 
AGEs-protein cross-linking. Among these, stilbene 1 
and 3 exhibited the higher inhibitory activity against 
AGEs formation after incubation at 37° C for 15 days, 
with an IC50 value of 24.5 and 28.7 µM respectively 
(Table 1). Methylglyoxal-mediated protein glycation 
inhibition was evaluated for isolated 1 to 3 (Table 1) 
which exhibited a substantial activity, although still 
less effective than that of aminoguanidine. The 
inhibitory effect of the three compounds and 
aminoguanidine had IC50 values of 1013.7 and 1018.4   
and 910.9 µM, respectively. Inter and intra molecular 
cross linking with collagen is formed as a result of 
glycation which is responsible for resistance to pepsin 
digestion. Treatment with isolated compounds and 
glibenclamide reversed these parameters with respect 
to the diabetic control. Treatment with isolated 
compounds and glibenclamide significantly reduced 
the levels of collagen linked fluorescence, which is in 
agreement with the in vitro BSA glycation study. 
Solubility pattern was also restored, with a relative 
increase in pepsin soluble collagen. These changes 
indicated a reduction in cross-linking of collagen 
proteins in isolated treated diabetic animals.   
The effect of 1-3 on the formation of AGEs in 
the GK-peptide/ribose system was then studied. This 
test is used to evaluate the ability of the extract to 
inhibit the crosslinking of GK-peptide in the presence 
of ribose. Compounds 1, 2, 3 and aminoguanidine 
were found to inhibit the formation of AGE 
(fluorescence) after 15 days of incubation, as shown in 
Table 2.  
Glucose reacts nonenzymatically with the   
NH2-terminal amino group of the β chain of human    
hemoglobin (HbA; α2β2) to form an aldimine linkage,   
which subsequently undergoes an Amadori 
rearrangement to form the more stable ketoamine 
linkage, resulting in the slow formation of HbA1c. 
Table 3 shows the amount of glycated hemoglobin (% 
GHb). When hemoglobin was used alone (NC), the 
amount of glycated hemoglobin was 8.9%. This 
noticeably increased with the addition of glucose to a 
27.6% (PC). Nonetheless, it decrease significantly 
with the treatment of 1, 2 and 3 and dropped further 
with the treatment of glutathione. The amount of 
hemoglobin A1c (%HbA1c), corresponds to a specific 
sub-fraction of glycated hemoglobin, it is lower than 
the amount of glycated hemoglobin. However, it 
showed a similar tendency in the percentage of 
glycation. This result indicates that compounds have 
the most potent glycation inhibition at the early stage 
of protein glycation at a concentration, of 5 mg/ml. 
These compounds can effectively prevent HbA1C 
formation.  
Glycosylated protein levels in blood serum of 
diabetic mice were significantly higher than those of 
control mice as expected. At the end of the experiment 
after treatment with the isolated compounds, 
glycosylated protein, in diabetic mice were 
statistically decreased (Table 3). 
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Table 2 
Percentage inhibition of crosslinked advanced glycation endproducts following reincubation of ribated 
lysozyme 
                        Treatment    (mM)                                                    Inhibition (%)  
 
1 
25 
50 
 
 
39 
57 
 
2 
25 
50 
 
 
27 
48 
 
3 
25 
50 
 
 
34 
52 
Aminoguanidine  
50 
 
 
60 
 
Table 3 
The inhibitory effects of chloroform extract and stilbenoids 1, 2 and 3 on glycosylated protein   and glycated  
hemoglobin (GHb and HbA1c) 
            Groups                             GHb                                 HbA1c                           Glycosylated protein    
                                                                                                                                                              
(nmol/mg protein)         
Negative control  
 
8.9 ± 0.09 7.8 ± 0.2 
15.2 ± 0.23
a
 
Positive control  
 
27.6 ± 0.12 18.6 ± 0.4 
23.6 ± 0.04 
Chloroform extract 20.4 ± 0.16
a
 
 
15.9 ± 0.6
a
 
18.7 ± 0.12
a
 
1 
 
9.8 ± 0.17
a
 10.0 ± 0.5
a
 
19.5 ± 0.14
a
 
2 
 
13.6 ± 0.09
a
 15.0 ± 0.3
a
 
17.2 ± 0.51
a
 
3 
 
10.1 ± 0.18
a
 12.7 ± 0.4
a
 
18.1 ± 0.07
a
 
Glutathione 
 
8.1 ± 0.08
a
 9.0 ± 1.1
a
 - 
Aminoguanidine 
 
- - 20.1 ± 0.07
a
 
Negative Control: Incubation with hemoglobin (30 mg/ml), positive control: Incubation with hemoglobin (30  
mg/ml) + glucose (0.278 mM), chloroform extract: Incubation with hemoglobin (30 mg/ dI) + glucose (0.278 mM) 
+ chloroform extract (20 mg/ ml), stilbenoids: Incubation with hemoglobin (30 mg/ dl) + glucose (0.278 mM) + 
stilbenoids (5 mg/ml), glutathione: Incubation with hemoglobin (3 mg/ dl) + glucose (2.7 mM) + glutathion (0.5 
mM). Data as expressed as ± SD; 
a
P < 0.05 vs positive control values.  
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Amphotericin B treatments at 5 and 10 µM 
significantly increased LDL oxidation levels as by 
determined MDA formation (Table 4, P < 0.05). 
However, the presence of the three isolated 
compounds at 5 µM significantly reduced 10 µM 
amphotericin B-induced LDL oxidation (Table 4, P < 
0.05). Compound, 2 was to be most effective agent.  
 
Table 4 
The prooxidant effect of amphotericin B (AB) at 5 and 10 µM, and  the antioxidant protection of 5 µM 1, 2 
and 3 against 10 µM, AB-induced malondialdehyde (MDA) formation (nmol/mg LDL protein) after a 48-h 
incubation at 37° C. 
                      Groups                                          MDA formation (nmol/mg LDL protein)             
Control 13.26 ± 2.16 
AB  5 µM 22.56 ± 5.72
a
 
AB  10 µM 34.29 ± 2.34
 a
 
AB  10 µM + 1(5 µM) 32.56 ± 1.89
 a
 
AB  10 µM + 2(5 µM) 28.42 ± 3.27
 a
 
AB  10 µM + 3(5 µM) 30.19 ± 5.81
 a
 
Values are expressed as Mean ± SD, 
a
Significantly (P < 0.05) different from control, where  the significance 
was performed by Oneway ANOVA followed by post hoc Dunnett´s test 
 
LDL treated with 50 mM glucose and EDTA 
significantly increased glycation level (Table 5, P < 
0.05). Under EDTA protection, the presence of the 
three bioactives at 5 µM significantly reduced LDL 
glycation, and the most powerful antiglycative agent 
was 1 (P < 0.05). On the other hand, both LDL 
oxidation and LDL glycation significantly increased 
when LDL was treated with 50 mM glucose without 
EDTA protection. Although the presence of three 
isolated at 5 and 10 µM significantly reduced both 
LDL oxidation and glycation when compared with 
controls (P < 0.05), the most antioxidative and 
antiglycative agent was 1.  
 
Table 5 
Protective effect of 5 µM, of 1, 2 and 3 on LDL  against 50 mM glucose-induced glycation and oxidation with 
or without 0.5 mM EDTA treatment 
                                                   With EDTA                                            Without EDTA 
Treatment                      Glycation                Oxidation                   Glycation                Oxidation 
LDL 2.8 ± 0.17 3.6 ± 0.63 3.8 ±  0.87 21.03 ± 2.10 
LDL+glucose 17.2 ± 3.32a 4.3 ± 1.56a 22.65 ± 3.45a 58.79 ± 3.86a 
1(5 µM) 4.6 ± 0.98b 2.9  ± 0.98,b 13.86 ± 2.74 a,b 41.78 ± 2.87 a,b 
2(5 µM) 10.4 ± 2.76 a,b 3.7 ± 0.62 b 18.59 ± 5.03 a,b 43.32 ± 4.39 a,b 
3(5 µM) 6.3 ± 1.80 a,b 3.2  ± 0.87,b 15.14 ± 2.96 a,b 46.50 ± 4.17 a,b 
Values are expressed as Mean ± SD (n = 6), 
a
Significantly (P < 0.05) different from LDL group. 
 
b
Significantly (P < 0.05) different from LDL+glucose, where the significance was performed by Oneway 
ANOVA followed by post hoc Dunnett´s test 
 
Advanced AGEs are a heterogeneous group of 
products arising from the non-enzymatic glycation and 
oxidation of proteins and lipids (Duell et al., 1990). 
They accumulate in diverse biological settings, such as 
diabetes, inflammation, renal failure, and aging 
(Ahmed, 2005). A number of natural and synthetic 
compounds have been proposed, discovered, or are 
currently being used as AGEs inhibitors (Dukic-
Stefanovic et al., 2001). The AGEs inhibitors, such as 
pyridoxamine, aminoguanidine and LR90, have been 
shown to prevent the development of complications in 
experimental diabetes (Degenhardt et al., 2002). In 
this study, PM inhibited advanced glycation end- 
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products-BSA formation in vitro and was less 
effective than the AGEs inhibitor aminoguanidine.  
Increased glycation during hyperglycaemia 
can cause intra or inter molecular cross-linking of 
proteins as they accumulate AGEs. Numerous studies 
have reported that buildup of cross-linked AGEs on 
long-lived proteins may underlie the development of 
health complications in subjects affected by diabetes 
or because of ageing (Ahmed, 2005). Furthermore, 
levels of serum AGEs reflect the severity of these 
complications whereas therapeutic interventions 
aimed at reducing AGEs can inhibit or delay their 
progression (Monnier, 2003). In this study we found 
that stilbenoids 1 and 3 inhibited formation of 
methylglyoxal derived AGEs in a bovine serum-
albumin-methylglyoxal system, and may also act by 
blocking conversion of dicarbonyl intermediates to 
AGEs.  This effect may be due to the unsubstituted 
carbons of compounds 1 and 3 at their position 6 on 
the A-ring, which is the best active sites for to trap 
reactive dicarbonyl species. This was consistent with 
previous finding by Sang et al (2007). 
Furthermore, ours results show that isolated 
compounds possesses Amadorin activity. Exposure of 
lysozyme to ribose for a period of 24 h generates 
glycated protein rich in Amadori but not advanced 
glycation adducts (Khalifah et al., 1999). 
Reincubation of this ribated lysozyme in the absence 
of sugar generates cross-linked AGEs as reported 
previously (Liggins and Furth, 1996) but their 
formation inhibited in the presence of PM. In addition 
to its antioxidant properties previously reported (Perez 
et al., 2010), the compounds isolated from PM could 
react with carbonyl groups from reducing sugars, 
Amadori adducts and dicarbonyl intermediates 
therefore blocking their conversion to advanced 
glycation end-products. Dicarbonyl intermediates such 
as methylglyoxal have received considerable attention 
as mediators of advanced glycation end-product 
formation and are known to react with lysine, arginine 
and cysteine residues in proteins to form 
glycosylamine protein crosslinks (Frye et al., 1998). 
Reincubation of dialyzed ribated lysozyme generated 
cross-linked advanced glycation end-products that 
were inhibited in the presence of increasing 
concentrations of analyzed compounds and 
aminoguanidine. All compounds have Amadorin 
activity and inhibit cross-linked advanced glycation 
end-products to concentrations of 5-50 mM.  
Amphotericin B, with a great affinity to the lipid part 
of the LDL particle, could extract cholesterol from 
LDL and sensitize the modified LDL to oxidation. The 
compounds in this study exhibited marked antioxidant 
protection against amphotericin B induced oxidation 
(Table 3). Nonenzymatic glycation of LDL is 
accompanied by oxidative, radical-generating 
reactions (Menzel et al., 1997). In the presence of 
EDTA, oxidation was not responsible for the observed 
glycation; in this instance, glycation may be due 
simply to the interaction between LDL protein and 
glucose. These properties may allow them to exhibit a 
great affinity to glucose and or LDL protein. 
Kidney weight, renal AGEs and mitochondrial 
thiobarbituric acid-reactive substance was very 
elevated in diabetic mice compared to the control 
group (Table 6). These levels were reduced to almost 
in range values by the administration of the different 
tested compounds. The mitochondrial thiobarbituric 
acid-reactive substance was increased to 2.09 
mmol/mg protein compared with the 1.81 mmol/mg 
protein of the control mice. Remarkably, levels in 
groups treated with isolated were significantly 
reduced. The level of glucose in the diabetic control 
group increased during the period of the experiment 
and the administration of isolated did not have an 
effect on it. Symptoms in diabetic animals are 
increased kidney lipid peroxidation (TBARS), 
reduction in antioxidant defense and increase in renal 
AGE. This was in agreement with the present study 
results that confirmed by Maillard-type fluorescent 
measurement, renal AGEs accumulation in 
streptozotocin-induced diabetic mice. For this reasons, 
we first assessed the effect of analyzed compounds on 
renal AGE accumulation and thiobarbituric acid 
reactive substance. Even though, a 10 days 
experimental period is not enough time to observe 
structural modifications in kidneys, it is important to 
prevent diabetic renal damage from the early stage.  
Collagen was measured in mice tail tendon 
after acid hydrolysis. Diabetic mice showed a 
significant increase in tail tendon collagen, collagen 
glycation and collagen linked f1uorescence and 
reduction in pepsin soluble collagen (Table 7). 
Treatment with 1 to 3 compounds and the control 
drug, glibenclamide, reversed these effects, indicating 
a potential role in preserving collagen structure and 
function during the pathogenesis of diabetes. The 
effect of stilbenoids at doses of 15 mg/kg was 
statistically (p < 0.05) comparable with that of 
glibenclamide. 
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CONCLUSIONS 
In summary, the data presented here clearly indicates 
that Prosthechea michuacana extract possesses in 
vitro inhibitory activity against AGEs formation. 
Ultimately, a strong inhibitory compounds on 
glycation were isolated from a chloroform extract of 
the bulbs of orchid P. michuacana and identified as α-
α´-dihydro, 3´,5´,2-trimethoxy-3-hydroxy-4-acetyl-4´-
isopentenyl stilbene, 4,6,7-trihydroxy-2-methoxy-8-
(methylbut-2-enylphenan-thren-1-1´-4´,6´,7´-
trihydroxy-2´-methoxy-8´-(methylbut-2´-enyl)-phenan 
-threne and gigantol. Isolated compounds possessed 
antioxidant, Amadory activities and inhibitory activity 
on AGEs formation. In streptozotocin-induced diabetic 
rats, to prevent and/or delay the onset of diabetic renal 
damage. Therefore, stilbenoids and phenantrenes from 
P. michuacana could be a candidate for use in studies 
looking at the effects of natural herbal complement in 
the prevention of diabetes complications, since it 
possesses both antioxidant and antyglycation 
activities. 
 
Table 6 
Effect of 1, 2, 3 on thiobarbituric acid-reactive substances in mitochondrial, renal weight 
and AGE levels 
             Groups                        Mitocondrial-TBA                    Renal Weight                    AGE 
                                              ( mmol/mg protein )                           (g)                                  (AU) 
Normoglucemic  
 
1.81 ± 0.039
a
  0.73 ± 0.067
a
  15.98 ± 3.12
a
 
Diabetic  
 
2.09 ± 0.026  1.08 ± 0.018  24.25 ± 3.90 
1  
 
1.87 ± 0.012
a
  0.96 ± 0.064
a
  13.10 ± 3.01
a
 
2  
 
1.95 ± 0.094
a
  1.0 ± 0.087
a
  16.23 ± 4.21
a
 
3  
 
1.85 ± 0.039
a
  0.95 ± 0.072
a
 13.26 ± 3.48
a
 
Aminoguanidine  
1.80 ± 0.058
a
  
 
0.97 ± 0.048
a
  12.87 ± 2.99
a
 
Data as expressed as ± SD; 
a
P < 0.05 vs. diabetic control values. 
 
 
Table 7 
Effect of 1, 2, 3 on the glycation of tail tendon collagen 
       Treatment             Total collagen             Pepsin digested            Collagen glycation                 Fluorescence                                                           
                                   (mg/100 mg tendon)  (mg/100 mg tendon)        (µg glucose/collagen)       (AU/mg collagen) 
Normal 
 
37.6 ± 1.86  3.46 ± 0.043  2.98 ± 0.65  2.85 ± 0.054  
Diabetic 
 
75.9 ± 0.98  1.47 ± 0.036  14.57 ± 0.79  24.63 ± 0.96  
Diabetic +1 
 
48.3 ± 1.43
 ab 
  2.13 ± 0.028
ab 
  8.20 ± 0.32
 ab 
  17.65 ± 0.54
 ab 
  
Diabetic + 2 
 
66.4 ± 1.78
 ab 
  1.74 ± 0.019
ab 
  10.69 ± 0.57
 ab 
 20.13 ± 1.03
 ab 
  
Diabetic + 3 
 
48.9 ± 2.06
ab 
 2.16 ± 0.026
 ab 
  8.53 ± 0.62
 ab 
  17.70 ± 0.79
ab
  
Diabetic + 
Glibenclamide 
 
47.1 ± 1.87
ab
  2.19 ± 0.020
 ab 
  8.09 ± 0.14
 ab 
  17.21 ± 0.72
 ab 
  
Data as expressed as ± SD; n=5; 
a
 vs normal control; 
b
 vs diabetic control. Concentration of analyzed 
compounds: 15 mg/kg pde peso 
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